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COMMENT&RESPONSE
MedicationsWith Depression as an Adverse Effect
To the Editor In a cross-sectional survey study, Dr Qato and
colleagues1 foundthat theuseofprescriptionmedicationswith
depression as a potential adverse effect was common. How-
ever, the authors did not take into account that most of the
drugs described are used to treat conditions already linked to
an increased risk of depressive symptoms. Although they in-
vestigated the relationshipbetweenhypertensionanddepres-
sion, they did not account for the association of depressive
symptomswithpain (and subsequentuse of pain killers), gas-
troesophageal reflux disorder (and subsequent use of gastro-
intestinal agents), or atopic disorders, such as asthma or al-
lergic rhinitis (and theuseofmontelukast andantihistamines).
Interestingly, these conditions are related to persistent low-
grade inflammation,2 an important factor associatedwithde-
pression, which could not be accounted for in the study.
The increase in prescription of such drugs follows the in-
creased prevalence and survival of people with chronic con-
ditions in the United States.3 In Table 1 in the article, the pa-
tients takingdrugs associatedwithdepression includedmore
women,olderpeople,widowedordivorcedpeople, andpeople
with higher levels of unemployment and obesity, factors also
associated with an increased risk of depression in nonmedi-
cated populations. This group also had more comorbidities,
whichmay have additive inflammatory and psychological ef-
fects. People with more than 1 medical comorbidity tend to
have more depressive symptoms, increasing with the num-
ber of disorders, without the etiology being related to ad-
verse drug reactions.4
The studydidnot investigate the converse—drugs that can
be associated with a reduction in risk of depressive symp-
toms. Anti-inflammatory drugs or drugs for other conditions
that exhibit anti-inflammatory properties, such as statins,
acetylsalicylic acid, somehypoglycemic agents, drugs that act
in the renin-angiotensin-aldosterone system, and immuno-
modulators, may have beneficial effects on mood, at least in
subgroups of people.5
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To the Editor Dr Qato and colleagues1 studied common pre-
scription drugs associated with depression as an adverse ef-
fect. The authors controlled for the number of self-reported
chronic conditions and performed sensitivity analysis of pa-
tients with hypertension. However, one factor that may play
a role in the results that the authors did not discuss is the se-
verity of illness of the patients.
More severe forms of chronic illnesses, such as hyperten-
sion, can be associated with higher levels of depressive
symptoms.2 Could it be thatmore severe forms of disease are
associated with the use of drugs that have depression listed
as an adverse effect? Cliniciansmay be less likely to prescribe
certain drugs unless a condition is severe and is uncontrolled
with other, more benign medications. For instance, in
primary care in the United Kingdom, most patients with hy-
pertension are not prescribed β-blockers unless their hyper-
tension is uncontrolledwith other agents.While the sensitiv-
ity analysis of patients with only hypertension showed
a statistically significant difference between those taking
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different types of drugs, it cannot take into account the sever-
ity of the condition. Could chronic illness severity be a con-
founder and play a role in causing depression, the choice of
drugs prescribed, and any resultant association?
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In ReplyDrsAgustini andBerk raise 3primary concerns regard-
ingour analysisdemonstratinganassociationbetween theuse
of prescriptionmedicationswithdepression as apotential ad-
verse effect and concurrent depression.
Their first concern is that we did not account for the as-
sociationbetweendepression andotherhealth conditions be-
sideshypertension—particularly conditions related to inflam-
mation, suchaspain andasthma,whichareoften treatedwith
medications, such as pain killers and antihistamines that are
associatedwith depressive symptoms. However, not all com-
monly used medications to treat these conditions, including
hypertension, are associatedwith an increased risk of depres-
sive symptoms. Specifically,manyof themost frequentlyused
nonsteroidal anti-inflammatory drugs (eg, ibuprofen), anti-
histamines (eg, cetirizine), and proton pump inhibitors
(eg, omeprazole and esomeprazole) were on our list of pre-
scriptionmedications with depression as a potential adverse
effect, although some nonsteroidal anti-inflammatory drugs
(eg, naproxen), antihistamines (eg, loratadine), and proton
pump inhibitors (eg, pantoprazole) were not.
Their second concern focuses on the importance of ac-
counting for sociodemographic characteristics, including age,
employment status, marital status, and comorbidity profiles
of adults. In all our adjusted analyses,we accounted for these
sociodemographic characteristics and comorbidities, mea-
suredasnumberofchronicconditions. In theseadjustedanaly-
ses,weonlyobservedadose-responseassociationbetweenthe
number of medications used and concurrent depression for
medications that have (vs donot have) depression as a poten-
tial adverse effect.
Their third concern is that we failed to incorporate infor-
mation in our analyses on prescriptionmedications thatmay
reduce the risk of depression, particularly those that exhibit
anti-inflammatoryproperties.We recognize the importanceof
the evolving literature on the role of inflammation and anti-
inflammatory drugs in depression. Although inflammation
does not appear to be necessary or sufficient for the develop-
ment of depressive symptoms for everyone, theremay a sub-
set of vulnerable individuals in whom inflammation plays an
important role.1
Dr Burch asserts thatmore severe forms of chronic illness,
including hypertension, may be associated with a higher risk
of depression and that we did not incorporate severity in our
analyses. While we agree that disease severity may be an
important confounder, evidence demonstrating an associa-
tionbetweendiseaseseverityanddepression is lacking, includ-
ing for hypertension.2
DimaM. Qato, PharmD, MPH, PhD
Mark Olfson, MD, MPH
Author Affiliations:Department of Pharmacy Systems, Outcomes and Policy,
University of Illinois at Chicago College of Pharmacy, Chicago (Qato);
Department of Psychiatry, Columbia University College of Physicians and
Surgeons, New York, New York (Olfson).
Corresponding Author:DimaM. Qato, PharmD, MPH, PhD, Department of
Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago
College of Pharmacy, 833 SWood St, Ste 266, Chicago, IL 60612
(dimaqato@uic.edu).
Conflict of Interest Disclosures: The authors have completed and submitted
the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Qato
reported serving as a consultant for the Public Citizen Health Research Group.
Dr Olfson reported receiving a grant from Janssen Scientific Affairs LLC to
Columbia University Medical Center.
1. Kiecolt-Glaser JK, Derry HM, Fagundes CP. Inflammation: depression fans the
flames and feasts on the heat. Am J Psychiatry. 2015;172(11):1075-1091. doi:10
.1176/appi.ajp.2015.15020152
2. Scalco AZ, Scalco MZ, Azul JBS, Lotufo Neto F. Hypertension and depression.
Clinics (Sao Paulo). 2005;60(3):241-250. doi:10.1590/S1807-
59322005000300010
Stress-RelatedDisorders andAutoimmuneDisease
To the Editor Dr Song and colleagues1 reported that stress-
relateddisorderswere associatedwith increased risk of subse-
quent autoimmune disease. Stress is an adverse event that is
associated with various mental disorders and physical dis-
eases, possibly through hypothalamic-pituitary-adrenal axis
dysregulation, epigenetic modification, or the inflammatory
response.2,3 The study presented several problems that re-
quire further discussion.
First, in individuals with a history of other psychiatric dis-
orders, Songandcolleagues1discovered that the riskofautoim-
mune disease was increased among patients with stress-
relateddisorders, comparedwithmatched individualswithout
stress-relateddisorders,but theriskofautoimmunediseasewas
not increased compared with full siblings (eg, for all stress-
related disorders, hazard ratio, 1.05; 95% CI, 0.88-1.25).
Considering that the study of siblingsmay decrease the poten-
tial effects of genes and environment, we believe that the re-
sult from siblings is more reliable. Therefore, stress-related
disorders may not be associated with an increased risk of
autoimmunedisease among individualswith ahistoryof other
mental disorders.
Second,Songandcolleagues1 found that thepersistentuse
of selective serotonin reuptake inhibitors (SSRIs) was associ-
atedwith a decreased risk of autoimmune disease among pa-
tientswithposttraumatic stressdisorder (PTSD)during the first
year after diagnosis. However, these results must be further
Letters
1816 JAMA November 6, 2018 Volume 320, Number 17 (Reprinted) jama.com
© 2018 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ Deakin University by Bruno Agustini on 05/08/2019
